Contact information Verified work emails, personal emails, and direct dials — unlocked in one click.
Work email
•••••@oculis.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••
Free to start · No credit card required
Current company Oculis
Biotechnology Research · 78 employees · Founded 2017 · Lausanne, Switzerland
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neurological diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S, Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. For more information, please visit: Forward-Looking Statements / Disclaimers: LinkedIn posts from Oculis may contain forward-looking statements regarding the timing, progress, and clinical potential of Oculis’ development programs and product candidates, including their intended benefits and market opportunity. These statements are based on current expectations and involve inherent risks and uncertainties including those described in Oculis’ SEC filings. Actual results may differ materially from those anticipated. Privosegtor and Licaminlimab are investigational drugs and have not been approved by the FDA or any other regulatory authority for commercial use in any country. For full corporate disclaimers, please visit https://investors.oculis.com/ and review Oculis’ SEC filings.